tiprankstipranks
Advertisement
Advertisement

EXEL Stock Latest News

Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL
Company AnnouncementsExelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL
7d ago
EXEL
Exelixis price target raised to $45 from $44 at Barclays
PremiumThe Fly
Exelixis price target raised to $45 from $44 at Barclays
10d ago
EXEL
Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
PremiumThe Fly
Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
1M ago
EXEL
RXRX
Exelixis price target lowered to $43 from $46 at RBC Capital
PremiumThe Fly
Exelixis price target lowered to $43 from $46 at RBC Capital
2M ago
MRK
EXEL
Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
PremiumRatings
Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
2M ago
EXEL
Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
PremiumRatingsExelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
2M ago
EXEL
Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs
Premium
Weekend Updates
Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs
2M ago
Z
LIN
Exelixis: Solid Financial Beat and Advancing Oncology Pipeline Drive Upgraded Earnings Outlook and $54 Price Target
Premium
Ratings
Exelixis: Solid Financial Beat and Advancing Oncology Pipeline Drive Upgraded Earnings Outlook and $54 Price Target
3M ago
EXEL
Exelixis price target raised to $54 from $52 at H.C. Wainwright
PremiumThe Fly
Exelixis price target raised to $54 from $52 at H.C. Wainwright
3M ago
EXEL
Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo
PremiumThe Fly
Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo
3M ago
EXEL
RCUS
Exelixis Earnings Call: CABOMETYX Strength, ZANZA Catalyst
PremiumCompany Announcements
Exelixis Earnings Call: CABOMETYX Strength, ZANZA Catalyst
3M ago
EXEL
Exelixis price target raised to $44 from $43 at Stifel
PremiumThe Fly
Exelixis price target raised to $44 from $43 at Stifel
3M ago
EXEL
Exelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
PremiumRatingsExelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
3M ago
EXEL
Exelixis reports Q4 EPS 94c, consensus 81c
Premium
The Fly
Exelixis reports Q4 EPS 94c, consensus 81c
3M ago
EXEL
Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.6B
Premium
The Fly
Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.6B
3M ago
EXEL
Exelixis (EXEL) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Exelixis (EXEL) Q4 Earnings Cheat Sheet
3M ago
EXEL
Exelixis price target raised to $44 from $41 at Barclays
PremiumThe Fly
Exelixis price target raised to $44 from $41 at Barclays
3M ago
EXEL
Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential
PremiumRatings
Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential
3M ago
EXEL
Exelixis reports zanzalintinib new drug application accepted for review by FDA
PremiumThe Fly
Exelixis reports zanzalintinib new drug application accepted for review by FDA
3M ago
EXEL
Exelixis price target raised to $49 from $48 at Morgan Stanley
PremiumThe FlyExelixis price target raised to $49 from $48 at Morgan Stanley
3M ago
EXEL
Exelixis price target raised to $52 from $49 at H.C. Wainwright
Premium
The Fly
Exelixis price target raised to $52 from $49 at H.C. Wainwright
3M ago
EXEL
Exelixis price target raised to $51 from $49 at Truist
Premium
The Fly
Exelixis price target raised to $51 from $49 at Truist
4M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >